Social··Severity 6
Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices
Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher solvent and freight costs due to the Middle East conflict further squeezed EBITDA margins.
Scenario chain
Probabilities below are model estimates based on the event chain, horizon, and indicators. They are not outcome guarantees, investment advice, or emergency instructions.
A
27%Эскалация
Forecast derived from cascade analysis. Watch confirmation indicators below.
Primary source: Economic Times
Checking access status…